The B2B Podcast Index
Index
All categories
MarketingSalesSaaSFinanceHROpsLeadershipCustomer SuccessAI & DataProductStartups & FoundersRevOpsEngineering & DevTools
MethodologySubmit
Best of:MarketingSalesSaaSFinanceHROpsLeadershipCustomer SuccessAI & DataProductStartups & FoundersRevOpsEngineering & DevTools
An independent project byFame
SearchBest episodesGuestsInsightsMethodologySubmit a podcast
#730PwC's Next in Health69.3 / 100Get badge
← The Index
PwC's Next in Health artwork
General▲1620 this period

PwC's Next in Health

Hosted by PwC's Health Industries

Listed under Health & Fitness, Business, Business › Management

Hosted by Glenn Hunzinger, US Health Industries Leader, the Next in Health podcast series offers insights on the most important issues facing pharma, medtech, and healthcare.

74 episodes · publishes fortnightly · latest 2026-07-30 · ~19 min/episode

Rank

#730

Substance

69.3

/ 100

Breakdown

Scored 2026-08
Updated monthly

General rank

#58 of 134

Across the index

#730 of 1878

Substance

Top 39%

outscores 61% of the index

Why it scores where it does

PwC's Next in Health ranks #730 on The B2B Podcast Index with a substance score of 69.3 out of 100, scored across 4 recent episodes. It scores highest on guest caliber and insight density. Three well-credentialed PwC leaders with relevant operational depth: Derek Scoob (actuarial/med-econ focus leading a 20-year survey of 110M+ lives), Phil Slifani (pharmaceutical cost and innovation strategy), Tom Bails (30+ years healthcare services experience, revenue cycle and policy expertise). These are practitioners with institutional authority and direct market access, though all are from a single firm perspective. They demonstrate genuine expertise in their domains but lack the diversity of external practitioners (hospital CFO, payer chief medical officer, employer benefit manager) that would strengthen guest caliber.

The five-dimension breakdown

Averaged across 4 recently scored episodes, with cited evidence.

Insight Density

14.3 / 20

The episode delivers solid baseline data and frameworks (55% labor costs, 90% of costs from chronic illness, 60% from hospitals/physicians) but relies heavily on frameworks and categories already well-known in healthcare finance. Novel insights are limited: the AI/coding arms race angle is fresh and substantive, but much of the discussion retreads familiar ground (GLP-1 utilization vs. price tradeoffs, behavioral health underinvestment, consolidation leverage). The discussion of No Surprises Act arbitration outcomes (88% provider win rate) is concrete and notable, but the episode doesn't push beyond surface-level explanation of why this is happening or what to do about it.

“55% of those costs are labor-related costs”

“90% of the total costs relate to patients with chronic and mental illness”

Originality

12.3 / 20

The episode largely recycles established narratives: consolidation driving costs, AI as cost driver, GLP-1 coverage decisions, behavioral health expansion, cell/gene therapy as emerging expensive innovation. The most original element is the detailed unpacking of the AI/coding arbitrage - framing it as an 'arms race' between provider documentation AI and payer validation AI - but even this is presented as emerging trend commentary rather than novel framework. The No Surprises Act arbitration data is relatively fresh reporting, but analysis remains descriptive rather than generative of new thinking.

“it becomes a bit of AI facing off on AI, validating benefits, medical policies”

“There's a long history of when there are changes in reimbursement or laws and policies that the participants in healthcare change to optimize for the economics”

Guest Caliber

15.3 / 20

Three well-credentialed PwC leaders with relevant operational depth: Derek Scoob (actuarial/med-econ focus leading a 20-year survey of 110M+ lives), Phil Slifani (pharmaceutical cost and innovation strategy), Tom Bails (30+ years healthcare services experience, revenue cycle and policy expertise). These are practitioners with institutional authority and direct market access, though all are from a single firm perspective. They demonstrate genuine expertise in their domains but lack the diversity of external practitioners (hospital CFO, payer chief medical officer, employer benefit manager) that would strengthen guest caliber.

“surveyed and interviewed chief actuaries and med-econ leaders at more than two dozen U.S. health plans”

“30 plus years of experience”

Specificity & Evidence

14.3 / 20

The episode includes concrete figures throughout: $6 trillion total US healthcare spend, 55% labor, 90% chronic/mental illness, 70% comorbidity, 60% hospital/physician costs, 110M+ lives surveyed, 100M+ employer-sponsored members, 8M ACA members, 88% provider win rate on No Surprises arbitration, GLP-1 price declines of 60-70%, potential 2-4x volume increases, $30-50 PMPM for GLP-1 coverage. However, specificity drops when discussing solutions and trend impacts - vague language around 'creative solutions,' 'a lot of these individual treatments,' and 'small PMPM impact' that accumulates. Few named companies, specific health systems, or plan examples.

“almost six trillion dollars”

“surveyed and interviewed chief actuaries and med-econ leaders at more than two dozen U.S. health plans”

Conversational Craft

13.3 / 20

Glenn Hunzinger functions as a moderator rather than a probing interviewer, largely cueing prepared remarks from panelists with softlob setup questions ("demystify that a little bit," "maybe talk a little bit about that too"). Follow-ups are rare and rarely challenge claims; when disagreement or tension surfaces (e.g., around utilization management's risks), the host acknowledges rather than presses. The structure feels more like a curated report walk-through than genuine dialogue. Tom Bails does occasionally offer substantive pushback on his own arguments (e.g., acknowledging bias in arbitration could cut both ways), but the host doesn't weaponize this tension. Questions tend to invite monologue rather than debate.

“Maybe for the listeners here, you know, just unpack in simple form what is it”

“Phil, you always love a hard question. So I'm gonna throw one at you”

Standout episodes

  • Behind the Numbers 2027: Understanding what's driving healthcare costs - and what it means for the future of healthcare

    2026-07-30

    81
  • US Pharma Deals Midyear Outlook 2026: Why Dealmakers Are Leaning Into Growth

    2026-06-24

    76
  • US Health Services Deals Midyear Outlook 2026: Why investors are focusing on resilience and value creation

    2026-06-25

    72

Rank over time

2 periods tracked.

Episodes

4 scored on substance · 61 tracked in total.

  • Behind the Numbers 2027: Understanding what's driving healthcare costs - and what it means for the future of healthcare

    2026-07-30 · 35 min

    81 / 100
  • US Medtech Deals Midyear Outlook 2026: Why companies are investing through uncertainty

    2026-06-25 · 12 min

    48 / 100
  • US Health Services Deals Midyear Outlook 2026: Why investors are focusing on resilience and value creation

    2026-06-25 · 9 min

    72 / 100
  • US Pharma Deals Midyear Outlook 2026: Why Dealmakers Are Leaning Into Growth

    2026-06-24 · 14 min

    76 / 100

Frequently asked

What is PwC's Next in Health's substance score?
PwC's Next in Health scores 69.3 out of 100 for substance and ranks #730 on The B2B Podcast Index. That puts it ahead of 61% of the B2B podcasts we rank and #58 of 134 in General. The score reflects insight density, originality, guest caliber, specificity and conversational craft across recent episodes - not downloads.
Is PwC's Next in Health worth listening to?
Yes - PwC's Next in Health outscores 61% of the B2B general podcasts and shows we rank on substance, so a general operator is likely to come away with something useful.
Who hosts PwC's Next in Health?
PwC's Next in Health is hosted by PwC's Health Industries.
How often does PwC's Next in Health publish?
PwC's Next in Health publishes fortnightly, has 74 episodes, released its most recent episode on 2026-07-30.
Which PwC's Next in Health episode should I start with?
Our highest-scoring recent episode is "Behind the Numbers 2027: Understanding what's driving healthcare costs - and what it means for the future of healthcare" (81/100) - a good place to start.

Show off your #58 rank in General

Add this badge to your site - it links back here and updates automatically as you rank.

Ranked #58 on The B2B Podcast Index
Embed code
<a href="https://index.fame.so/show/pwc-39-s-next-in-health" target="_blank" rel="noopener">
  <img src="https://index.fame.so/badge/pwc-39-s-next-in-health/badge.svg" alt="Ranked #58 on The B2B Podcast Index" width="360" height="136" />
</a>
Markdown & other formats →

Track PwC's Next in Health's rank

Get an email whenever this show moves up or down the Index. Monthly at most, no spam.

Listen / subscribe:WebsiteRSS

Frequently discusses

Companies, products and tools that come up most across this show's episodes.

PwC · 3JP MorganESCO

Guests who've appeared

Tom BailsDerek ScoobPhil SlifaniJames WoodsDan ForrellRule Vandenacker

Topics this show covers

The themes that come up most across this show's episodes.

Qualified Payment Amount (QPA)cell and gene therapyPwC's Behind the Numbers 2027 reportAI-powered ambient scribing and coding toolsProvider consolidation and physician employmentGLP-1 drugs and weight loss therapeuticsBehavioral health and mental health servicesNo Surprises Act and arbitrationPayment integrity AISite of care managementportfolio optimizationmedtech M&Aconnected carecardiovascular devicesstructural heartintravascular lithotripsyelectrophysiologyrobotics in healthcare

More General podcasts

  • CareTalk: Healthcare. Unfiltered.

    CareTalk: Healthcare. Unfiltered.

    87.0
  • Money Code

    Stablecon

    85.0
  • Reshaping Workflows with Dell Pro Precision and NVIDIA RTX PRO GPUs

    Dell Technologies AI Factory with NVIDIA

    85.0
  • The RAG Podcast

    Sean Anderson

    84.6
  • Outthinkers

    Outthinker

    83.6
  • Business Scholarship Podcast

    Andrew Jennings

    83.0

Similar shows

Podcasts that dig into the same topics.

  • CareTalk: Healthcare. Unfiltered.

    CareTalk: Healthcare. Unfiltered.

    87.0
  • The Private Equity Podcast, by Raw Selection

    Alex Rawlings

    76.0
  • HealthTech Hour

    Steve Roest

    74.4
  • Sales Leadership with Fexingo

    Fexingo

    69.4
  • B2B Sales Trends

    Global Performance Group

    69.0
  • The B2B Podcast

    GlobalData Marketing Solutions

    63.0